[ad_1] Our clinical study, highlighting the need for better therapy, was picked up by Ophthalmology Advisor: Longer Term Anti-VEGF Outcomes in Neovascular AMD, Diabetic and Vein Occlusion Related Macular Edema: #retina #AMD #diabeticretinopathy https://t.co/uUMf8y1V2M [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1] RT @ThomasCiullaMD: Our recent paper was “Editor’s Choice”: This post hoc analysis compared #suprachoroidal triamcinolone acetonide (CLS-TA… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1]
RT @ModernRetina: @BauschRetina and @clearsidebio are rolling out the new therapeutic, approved by the FDA for suprachoroidal use for the t…
[ad_2]
Source by Thomas Ciulla, MD, MBA
[ad_1] RT @RetinalPhys: Read about the commercial launch of Xipere and more industry news in the eUpdate: https://t.co/opmf3Pc1D6 [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1] This webinar on #suprachoroidal delivery features an amazingly talented team: https://t.co/S0LmnWUSqm [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1]
RT @ThomasCiullaMD: Just published in AJO: https://t.co/3CP1ggDwGG “Optical Coherence Tomography Anatomic and Temporal Biomarkers in Uveiti…
[ad_2]
Source by Thomas Ciulla, MD, MBA
[ad_1] RT @Healio_OSN: Xipere, the first @US_FDA-approved therapy for suprachoroidal use for the treatment of #macularedema associated with #uveit… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1] Just published: https://t.co/pGZQQVEySc Disease progression pathways of wet AMD: opportunities for new target discovery #eye #retina #AMD #maculardegeneration #drugdevelopment #clinicalresearch https://t.co/88KsrAeidf [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1]
Excited about the first FDA-approved therapeutic delivered into the #suprachoroidal space! https://t.co/L4NackGcXi
[ad_2]
Source by Thomas Ciulla, MD, MBA
[ad_1] RT @ThomasCiullaMD: Honored to be recognized as a Castle Connolly Top Doctor, by peer vote, for 2022, and for the past 10 years. https://t.… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.